<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1321489" disease_type="Neoplastic Process" abbrv="">Muir-Torre syndrome</z:e> (MTS) is a rare <z:e sem="disease" ids="C0037277" disease_type="Disease or Syndrome" abbrv="">genodermatosis</z:e> considered a subtype of <z:e sem="disease" ids="C1333990" disease_type="Neoplastic Process" abbrv="">hereditary nonpolyposis colorectal cancer</z:e> and traditionally associated with mutations in the mismatch repair genes </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: We describe a 51-year-old male with primary manifestations of recurrent <z:mpath ids='MPATH_230'>sebaceous adenoma</z:mpath> of the upper eyelid, a positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> family history, and metachronous occurrence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHOD: The diagnosis of MTS was established based on the clinical course, family history, and histopathologic findings, although further immunohistologic testing revealed the absence of MSH2 mutation </plain></SENT>
<SENT sid="3" pm="."><plain>We additionally performed an updated summary of published MTS cases with sebaceous <z:hpo ids='HP_0002664'>neoplasms</z:hpo> originating from the eyelid and conjunctiva for the period 2005 to 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: This patient, the second Greek case described in the international literature, is of interest mainly because of the metachronous occurrence of the visceral <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in combination with the absence of MSH2 mutation </plain></SENT>
<SENT sid="5" pm="."><plain>The need for high clinical suspicion for MTS in cases with sebaceous lesions of the periocular region should therefore be reinforced regardless of the mutational screening test undertaken </plain></SENT>
</text></document>